Last reviewed · How we verify
ABP 959
ABP 959 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
ABP 959 is a RANKL inhibitor that blocks osteoclast activation and bone resorption. Used for Giant cell tumor of bone, Bone metastases.
At a glance
| Generic name | ABP 959 |
|---|---|
| Also known as | Treatment T |
| Sponsor | Amgen |
| Drug class | RANKL inhibitor |
| Target | RANKL |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Oncology |
| Phase | Phase 3 |
Mechanism of action
ABP 959 targets RANKL (receptor activator of nuclear factor kappa-B ligand), a key mediator of osteoclast differentiation and activation. By inhibiting RANKL signaling, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss. This mechanism is similar to denosumab, an established RANKL inhibitor.
Approved indications
- Giant cell tumor of bone
- Bone metastases
Common side effects
- Hypocalcemia
- Osteonecrosis of the jaw
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |